Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

159.96 +1.76 (+1.11%)

Streaming Delayed Price Updated: 2:51 PM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Novartis AG Common Stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

41 42 Next >

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

April 24, 2025

NOVARTIS AG-SPONSORED ADR has a stellar value proposition. NYSE:NVS not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.

Via Chartmill

Roche Plans $50 Billion US Investment Over 5 Years With 12,000 New Jobs ↗

April 22, 2025

Roche to invest $50 billion in U.S. over five years, adding 12,000+ jobs and expanding manufacturing, R&D, and export capacity across eight states.

Via Benzinga

S&P 500, Nasdaq Futures Rise After Stocks Dip Amid Trump's Jabs At Powell, Strong Yen Gives Nikkei A Volatile Start ↗

April 21, 2025

U.S. stock futures rose Monday night even as Wall Street had a rough start to the week, amid growing concerns regarding the Federal Reserve's independence, and President Donald Trump's repeated attacks...

Via Benzinga

3 Momentum Stocks That Could Soar Post-Market Volatility

April 21, 2025

Three unexpected companies have rallied quickly in the period following tariff-related market turbulence; can they maintain momentum?

Via MarketBeat

Topics Artificial Intelligence World Trade

Food for Thought: Results from a Food Allergy Survey of Caregivers

April 17, 2025

(BPT) - What is it like for millions of American families managing food allergies? To better understand these experiences, Genentech, a member of the Roche Group, and the Novartis Pharmaceuticals...

Via Brandpoint

2 Dividend Stocks Defying the Tariff-Fueled Market Correction to Buy and Hold Forever ↗

April 17, 2025

Via The Motley Fool

Topics Government World Trade

Novartis Commits $23 Billion To Expand US Manufacturing Over Five Years, Despite Tariffs Uncertainties ↗

April 11, 2025

Novartis commits $23 billion to expand U.S. manufacturing and R&D with 10 new facilities, aiming to produce all key U.S. medicines domestically and add thousands of jobs.

Via Benzinga

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

Dow Jones, S&P 500 Pharma Names Slammed As New Trump Tariffs Target Drug Imports ↗

April 09, 2025

Big pharmaceutical names plowed lower Wednesday after Trump on Tuesday said that tariffs would take aim at drug imports.

Via Investor's Business Daily

Topics Government Stocks World Trade

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst ↗

April 08, 2025

Legend Biotech's Carvykti shows strong efficacy in multiple myeloma as U.S.-based manufacturing shields it from tariffs and global regulatory risks.

Via Benzinga

Topics World Trade

3 Health Care Stocks Whale Activity In Today's Session ↗

April 08, 2025

Via Benzinga

Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year ↗

April 03, 2025

FDA grants accelerated approval to Novartis' Vanrafia for IgA nephropathy, with Phase 3 data in 2026 expected to support traditional approval.

Via Benzinga

Novartis Pops — Hammering Rival Travere Therapeutics — On Its Kidney Drug Approval ↗

April 03, 2025

The companies are going head to head in kidney disease. Here's why Novartis could have a slight advantage.

Via Investor's Business Daily

FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals ↗

April 01, 2025

Apellis' Empaveli receives FDA Priority Review for rare kidney diseases C3G and IC-MPGN. Phase 3 data show strong efficacy in proteinuria reduction.

Via Benzinga

The Top 3 Vanguard ETFs of 2025 (so Far) Share This 1 Striking Common Denominator ↗

March 30, 2025

Via The Motley Fool

Topics Bonds ETFs

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) Technical Analysis observations. ↗

March 29, 2025

Exploring NOVARTIS AG-SPONSORED ADR's Technical Signals and Breakout Potential: Promising Signs: NOVARTIS AG-SPONSORED ADR Setting the Stage for a Breakout.

Via Chartmill

No Fear And No Panic After A 10% Correction = No Bottom ↗

March 28, 2025

In this video lesson, I discuss the overall market, my books, and my game plan moving forward after Friday's ugly sell-off.

Via Talk Markets

Topics Stocks / Equities

FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool ↗

March 28, 2025

FDA approves Novartis' Pluvicto for advanced prostate cancer patients who have received ARPI therapy.

Via Benzinga

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is an undervalued gem with solid fundamentals. ↗

March 26, 2025

NOVARTIS AG-SPONSORED ADR has caught the attention as a great value stock. NYSE:NVS excels in profitability, solvency, and liquidity, all while being very reasonably priced.

Via Chartmill

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

FDA Approves Expanded Use Of Novartis Rare Disease Drug As Only Treatment For Rare Type Of Kidney Disease ↗

March 21, 2025

Novartis' Fabhalta receives FDA approval for C3 glomerulopathy, expanding its kidney disease portfolio as global regulatory reviews continue.

Via Benzinga

Novartis Partner Monte Rosa Therapeutics Touts Positive Data From Early-Stage Study Of Investigational Drug Candidate For Immune-Mediated Disorders ↗

March 20, 2025

Monte Rosa's MRT-6160 shows promising Phase 1 results, with Novartis backing its development in a deal that could reach $2.1B in milestone payments.

Via Benzinga

Novartis New Data From Single-Dose Gene Therapy Shows Meaningful Efficacy, Safety In Patients With Spinal Muscular Atrophy ↗

March 19, 2025

Novartis' OAV101 IT gene therapy showed positive results in Phase 3 trials for SMA, with data supporting its potential as a treatment option.

Via Benzinga

The Best Vanguard ETF to Invest $1,000 in Right Now ↗

March 18, 2025

Via The Motley Fool

Topics ETFs

These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy? ↗

March 11, 2025

Via The Motley Fool

Topics ETFs Stocks

Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss ↗

March 06, 2025

Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.

Via Benzinga

Novartis Earns Near-Best Overall Rating As Profit Growth Climbs ↗

March 05, 2025

Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.

Via Investor's Business Daily

NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 04, 2025

Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.

Via Chartmill

Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction ↗

March 04, 2025

Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.

Via Investor's Business Daily

Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy ↗

March 03, 2025

Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.

Via Benzinga

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

41 42 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.